Table 3.

Conclusions and recommendations

Topics	Conclusions and recommendations
Dosage of infliximab	Based on several controlled clinical studies, certain standard dosage regimens for infliximab have been defined which probably need some re-evaluation in terms of improving benefit : risk ratios [44].
Future studies are needed to study the pharmacokinetic–pharmacodynamic relationship of infliximab as a necessary step before therapeutic drug monitoring can be recommended in guidelines.
Monitoring vital signs	Routine scheduled measurement of vital signs during infusion is not valuable in detecting acute infusion reactions and should only be performed in the case of an acute infusion reaction
We recommend to administer infliximab at an infusion unit under supervision of trained personnel. This approach enables direct interventions in case a patient reports symptoms. Baseline assessment of patients, including vital signs, should still be performed as normal clinical practice to rule out possible infections or other contraindications for infusion with infliximab.
Use of concomitant medication	Efforts should be made to establish a reasonable time interval in which concomitant medication should be decreased.
Loss of response to infliximab	Although some evidence exists that interval reduction might be more effective in raising serum infliximab concentrations than dosage increase, large randomized trials are needed to observe whether or not interval reduction is superior to dosage increase and in which subset of patients, in order to be able to give guidance regarding loss of response in clinical guidelines.